Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that Almirall has received the European Commission (EC) approval for ILUMETRI® (tildrakizumab) for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy. As indicated by Almirall, roll out of ILUMETRI® in Europe will start in the next few weeks. In July 2016, Sun Pharma out-licensed tildrakizumab to Almirall, for the development and commercialization of the product for psoriasis in Europe.
Tildrakizumab is a humanized high-affinity anti-IL-23p19 monoclonal antibody1. Due to its specific mechanism of action, it selectively blocks interleukin-23 (IL-23), an upstream inflammatory mediator cytokine, and acts by modifying the pathogenesis of the disease with limited impact on the rest of the immune system.
Its approval in Europe is based on the positive results from reSURFACE 1 and 2 phase-3 clinical trials3, presented for the first time in October 2016 at the 25th European Academy of Dermatology and Venerology (EADV) Congress in Vienna (Austria). Both pivotal phase-3 clinical trials, which included over 1,800 patients from more than 200 clinical sites worldwide, showed ILUMETRI® has a high level of safety and efficacy.
According to both studies data, an average of 63% of patients achieved 75% of skin clearance (Psoriasis Area Sensitivity Index or PASI 75) by week 12 and an average of 78% at week 28. Moreover, an average of 59% of patients achieved PASI 90 and an average of 30% reached PASI 100 at week 28. Over a year, more than 92% of patients who responded to ILUMETRI® within 28 weeks maintained a PASI 75 response.
Moreover, the results of a pooled analysis through three years2 from resurface 1 and 2 phase-3 trials show the consistent maintenance of efficacy and safety over three years of ILUMETRI® in patients with moderate-to-severe chronic plaque psoriasis who were responders at week 28. According to the data, PASI 75 responses were maintained with continued treatment with ILUMETRI® in 90% of patients up to week 1482 . ILUMETRI® was well-tolerated with very low drug-related serious adverse events and discontinuation rates.
Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.642.3 as compared to the previous close of Rs. 646.15. The total number of shares traded during the day was 321970 in over 5595 trades.
The stock hit an intraday high of Rs. 655.75 and intraday low of 640. The net turnover during the day was Rs. 209131797.